Drug intelligence / Profile preview

SASPject PT3.9

Development stage: Unknown
Lead developer: SASPiPhi
Modality: Oncolytic Viruses → Oncolytic Therapeutics
Administration: Intravenous

Overview

**SASPject PT3.9** is an engineered bacteriophage-based antibacterial therapy developed by Phico Therapeutics using the proprietary SASPject platform. It employs modified bacteriophages to deliver a gene encoding small acid-soluble spore proteins (SASPs) specifically to **Pseudomonas aeruginosa**, a multidrug-resistant pathogen responsible for severe hospital-acquired infections like ventilator-associated pneumonia. Inside target bacteria, the gene produces SASPs that bind and inactivate bacterial DNA, halting metabolism and reproduction without affecting host cells; this sequence-independent mechanism minimizes resistance development, addressing critical needs in antimicrobial resistance.[1][2][5]

Other names: SASPject Pseudomonas aeruginosa therapy

Targets

Neuraminidase

Beyond the preview

Go deeper on SASPject PT3.9.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SASPject PT3.9.

Explore the full profile